VRTX · News · 20260818N

Revenue Performance and Mix

VERTEX PHARMACEUTICALS INC / MA · 2026-08-18 · Importance 47 · Surprise 22 · No source text

Vertex Pharmaceuticals reported quarterly revenue of $3.33 billion, up 12.5% year over year. Revenue exceeded consensus expectations despite the company missing the consensus EPS estimate by $0.01 per share. The reported revenue increase exceeded the materiality threshold of $100 million and the 10% year-over-year change criterion.

Key facts

• Vertex Pharmaceuticals reported a 12.5% year-over-year revenue increase to $3.33 billion. source
• Vertex Pharmaceuticals missed consensus earnings estimates by $0.01 per share. source
• Cornerstone Advisors LLC purchased 24,760 shares of Vertex Pharmaceuticals valued at approximately $12.3 million in the second quarter. source
• Grandfield & Dodd LLC acquired 24,838 shares of Vertex Pharmaceuticals valued at approximately $12.34 million during the second quarter. source
• Commerzbank Aktiengesellschaft FI acquired 6,857 shares of Vertex Pharmaceuticals valued at approximately $3.41 million. source
• Vertex Pharmaceuticals' shares closed at $528.19 after gaining 2.45% on Tuesday. source
• Vertex Pharmaceuticals narrowly missed consensus EPS estimates. source
• Vertex Pharmaceuticals exceeded revenue expectations in its recent earnings report. source

Impact estimates